Nerandr Neratinib Tablets

I. Drug Name

Generic Name: Neratinib Maleate Tablets

Brand Names: Nerlynx, Helian, Nerandr

Dosage Form: Oral Tablets

Specification: 40 mg per tablet; 90 tablets per box

Manufacturer: INDAR Pharmaceuticals Pvt Ltd

II. Indications and Usage

This product is an irreversible pan-HER tyrosine kinase inhibitor indicated for:

1.  Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: Indicated for adult patients within one year of completing adjuvant trastuzumab-based therapy, to reduce the risk of recurrence.

2.  Advanced or Metastatic HER2-Positive Breast Cancer: In combination with capecitabine, indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens.

III. Dosage and Administration

Recommended Dosage:

Early-Stage Breast Cancer (Monotherapy): 240 mg (i.e., six 40 mg tablets) orally once daily for one year.

Metastatic Breast Cancer (in combination with capecitabine): 240 mg orally once daily on Days 1 through 21 of each 21-day cycle; the recommended dosage for capecitabine is 750 mg/m² orally twice daily on Days 1 through 14 of each cycle.

Administration: Take with food. Tablets should be swallowed whole; do not crush, chew, or split the tablets.

Prophylactic Antidiarrheal Regimen: Crucial! Prophylaxis with loperamide (Imodium) must be initiated concurrently with the first dose of neratinib. The standard regimen is: During the first treatment cycle (56 days)—Days 1 through 14: 4 mg orally four times daily; Days 15 through 56: 4 mg orally twice daily. Thereafter, loperamide may be continued as needed to control diarrhea.

Dosage Adjustment: Depending on the severity and duration of adverse reactions (such as diarrhea), measures such as temporary interruption of treatment or dose reduction to 200 mg, 160 mg, or 120 mg may be implemented. IV. Contraindications

Patients with a known hypersensitivity to neratinib or to any of the excipients.

V. Warnings and Precautions

1. Diarrhea:

Diarrhea occurs in almost all patients, with an incidence of severe diarrhea reaching up to 40%. It may occur early in the course of treatment (median time to onset is Day 8) and may lead to dehydration, electrolyte imbalances, and renal impairment.

Prevention, monitoring, and early aggressive intervention (including the use of loperamide, hydration, electrolyte replacement, and, if necessary, other antidiarrheal agents or temporary interruption/dose reduction of neratinib) must be implemented in accordance with established guidelines.

2. Hepatotoxicity:

Neratinib may cause elevations in liver transaminases. Liver function should be monitored regularly (e.g., monthly) prior to and during treatment. In the event of severe hepatic impairment, treatment should be temporarily interrupted, the dose reduced, or the drug permanently discontinued.

3. Embryo-Fetal Toxicity:

Neratinib may cause fetal harm. The pregnancy status of women of reproductive potential must be verified prior to initiating treatment. Patients must use effective non-hormonal methods of contraception during treatment and for at least 1 month following the last dose (as neratinib may reduce the efficacy of hormonal contraceptives).

VI. Adverse Reactions

Very Common (>20%) and Major Adverse Reactions:

Gastrointestinal: Diarrhea (incidence >90%), nausea, abdominal pain, vomiting, decreased appetite, dyspepsia.

Skin and Subcutaneous Tissue: Rash, dermatitis.

Systemic Reactions: Fatigue.

Musculoskeletal: Muscle spasms.

Hepatic: Elevated transaminases.

Other: Dry mouth, weight loss.

Common Serious Adverse Reactions: Diarrhea, vomiting, nausea, dehydration, acute renal impairment.

VII. Drug Interactions

Proton Pump Inhibitors (PPIs, e.g., omeprazole), H2-receptor antagonists, and Antacids: These agents significantly reduce neratinib plasma concentrations, thereby reducing its efficacy. Concomitant use should be avoided. It is recommended that neratinib be taken at least 3 hours before or at least 3 hours after taking antacids. Strong or Moderate CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort): These agents can significantly reduce neratinib plasma concentrations; co-administration should be avoided.

Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin): These agents may increase neratinib exposure, thereby increasing the risk of adverse reactions. Close monitoring is required during co-administration, and a reduction in the neratinib dosage may be considered.

P-gp Substrates (e.g., digoxin): Neratinib may increase the plasma concentrations of these agents; digoxin plasma concentrations should be monitored during co-administration.

VIII. Use in Specific Populations

Hepatic Impairment: No dosage adjustment is required for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the dosage should be reduced to 160 mg. Use should be avoided in patients with severe hepatic impairment.

Renal Impairment: No dosage adjustment is required for patients with mild to moderate renal impairment. Data are limited for patients with severe renal impairment or end-stage renal disease; use with caution in these populations.

Pediatric Use: Safety and efficacy have not been established.

Geriatric Use: No specific adjustment to the starting dosage is required; however, elderly patients may have lower tolerance for diarrhea and require close monitoring.

IX. Pharmacological Actions

Pharmacological Class: Irreversible pan-HER tyrosine kinase inhibitor.

Mechanism of Action: Neratinib covalently binds to the kinase domains of HER1 (EGFR), HER2, and HER4, thereby irreversibly inhibiting their kinase activity and blocking downstream signal transduction. This action inhibits tumor cell proliferation and growth. In the context of early-stage breast cancer, its primary role lies in eradicating potential microscopic residual disease.

X. Storage

Store at room temperature (20°C–25°C).

Keep the medication in its original packaging to protect it from moisture.

Keep out of the reach of children.

Important Note:

This package insert is not a substitute for professional medical advice. Before using neratinib, patients must undergo a comprehensive evaluation by a specialist physician and strictly adhere to the detailed medication instructions provided by their physician and pharmacist. Prophylactic and comprehensive management of diarrhea is central to the safe use of this medication. Regular monitoring and follow-up are mandatory during the course of treatment.

**Product Specifications**

**Product Name:** Neratinib Maleate Tablets 40 mg (90 tablets/box) — Nerandr Neratinib Tablets

**Common Name:** Neratinib Maleate Tablets

**Active Ingredient:** Neratinib Maleate

**Dosage Form:** Tablets

**Specification:** 40 mg per tablet; 90 tablets per box

**Manufacturer:** INDAR Pharmaceuticals Pvt Ltd

**Indications:** This product is an irreversible pan-HER tyrosine kinase inhibitor indicated for:

1. **Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer:** Indicated for adult patients within one year of completing adjuvant trastuzumab-based therapy, to reduce the risk of recurrence.

2. **Advanced or Metastatic HER2-Positive Breast Cancer:** In combination with capecitabine, indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens.

**Dosage and Administration:** **Recommended Dosage:**

**Early-Stage Breast Cancer (Monotherapy):** 240 mg (i.e., 6 tablets of 40 mg) orally once daily, taken continuously for one year.

**Metastatic Breast Cancer (in combination with Capecitabine):** 240 mg orally once daily, taken on Days 1 through 21 of each 21-day cycle; the recommended dosage for capecitabine is 750 mg/m² orally twice daily, taken on Days 1 through 14 of each cycle.

**Administration:** Take with food. Tablets should be swallowed whole; do not crush, chew, or split the tablets.

**Prophylactic Antidiarrheal Regimen:** **Crucial!** Prophylaxis with loperamide (Imodium) must be initiated concurrently with the first dose of neratinib. The standard regimen is: During the first treatment cycle (56 days)—Days 1 through 14: 4 mg orally four times daily; Days 15 through 56: 4 mg orally twice daily. Thereafter, loperamide may be continued as needed to control diarrhea. Dosage Adjustment: Depending on the severity and duration of adverse reactions—such as diarrhea—measures such as temporarily suspending treatment or reducing the dose to 200 mg, 160 mg, or 120 mg may be implemented.